Loading company…

ABBOTT LABORATORIES

ABTCIK 000000180019 fiscal years, 68 SEC filings

RevenueFY2025

$44.33B5.7%

Net incomeFY2025

$6.52B51.3%

Free cash flowFY2025

$7.39B16.4%

Diluted EPSFY2025

$3.7251.3%

Trends

FY2007–FY2025 · hover a year for its filing

Revenue & net incomeRevenueNet income

revenue 1.7× since FY2007 · net margin 13.9% → 14.7%

MarginsNet marginFCF margin

FY2025: net 14.7% · free cash flow 16.7% of revenue

Cash flowOperating cash flowFree cash flow

FY2025: $9.57B operating cash − $2.17B capex = $7.39B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 28% (FY2008) → 13% (FY2025) · on assets 7.5%

USD millions, except per-share values; share counts in millions. Click a value to open its filing; hover for the XBRL tag.

USD millions	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014
Revenue	44,328	41,950	40,109	43,653	43,075	34,608	31,904	30,578	27,390	20,853	20,405	20,247
Net income	6,524	13,402	5,723	6,933	7,071	4,495	3,687	2,368	477	1,400	4,423	2,284
Diluted EPS	3.72	7.64	3.26	3.91	3.94	2.50	2.06	1.33	0.27	0.94	2.92	1.49
Diluted shares	1,748	1,748	1,749	1,764	1,789	1,786	1,781	1,770	1,749	1,483	1,506	1,527
Operating cash flow	9,566	8,558	7,261	9,581	10,533	7,901	6,136	6,300	5,570	3,203	2,966	3,675
Capital expenditures	2,171	2,207	2,202	1,777	1,885	2,177	1,638	1,394	1,135	1,121	1,110	1,077
Free cash flow	7,395	6,351	5,059	7,804	8,648	5,724	4,498	4,906	4,435	2,082	1,856	2,598
Cash & equivalents	8,522	7,616	6,896	9,882	9,799	6,838	3,860	3,844	9,407	18,620	5,001	4,063
Total assets	86,713	81,414	73,214	74,438	75,196	72,548	67,887	67,173	76,250	52,666	41,247	41,207
Shareholders' equity	52,130	47,664	38,603	36,686	35,802	32,784	31,088	30,524	30,897	20,538	21,211	21,526

As reported in SEC filings; a missing tag shows “—”, never zero. Free cash flow is operating cash flow − capex. Methodology